MYCPE ONE Academy Launches the Most Affordable CPA (US) Exam Prep Course in India
Built for students and professionals looking to prepare for the CPA (US) exam with expert support, complete resources and less financial burden.
AHMEDABAD, India , May 29, 2025 /PRNewswire/ — MYCPE ONE Academy, an initiative by MYCPE ONE focused on making global professional education affordable and accessible, has launched a comprehensive CPA (US) Exam Prep Course at just ₹9,999. Designed for students and professionals aiming to pursue the CPA (US) qualification, this course makes exam prep accessible, without the usual high price tag.
Started in 2023, MYCPE ONE Academy was founded with the vision to democratize professional education and make it truly affordable. It currently supports over 2000 students through for EA, CMA (US) , and now the CPA (US). The Academy is committed to helping learners across backgrounds gain global credentials without cost being a barrier.
The Certified Public Accountant (CPA) designation is one of the most recognized global accounting credentials. It opens doors to top roles in accounting, audit, and finance across firms worldwide. However, the cost of coaching has often limited the access to it. MYCPE ONE Academy is changing that.
Course Highlights: 100+ Video Lectures (70+ Hours)
9,000+ Multiple Choice Questions (MCQs)
500+ Task-Based Simulations (TBS)
Full Coverage of All 6 Papers (3 Core & 3 Disciplinary Subjects)
100% Video-Based Learning
2,000+ Students Already Enrolled
Mock Examination
The course is fully aligned with the latest CPA (US) Blueprint by AICPA and the video-based format gives learners complete flexibility to study at their own pace, revisit complex topics as needed, and seamlessly integrate learning into their busy schedules.
Be it a working professional or a student pursuing accounting or finance, this course helps to build confidence through consistent practice, guided learning, and mentor support – ensuring clarity and consistency throughout the preparation journey.
'We're proud to announce the launch of the world's most affordable CPA (US) Course, built to make top-tier professional education truly accessible. We believe cost should never be a barrier to ambition. This course offers practical, exam-focused learning, guided by experienced educators, at a fraction of the traditional price,' said Shawn (Shalin) Parikh , Co-Founder & CEO, MYCPE ONE. 'Our endeavour is to empower 100,000 aspiring CPAs over the next 5-10 years with the skills, knowledge, and support they need to succeed. It's a collective effort of team to democratize access to one of the most respected global credentials in accounting,' he added.
'The CPA (US) is not just a credential – it's a powerful stepping stone to global recognition and leadership. To be honest, with the right mindset and guided preparation, this course is easier than most think – truly everyone's cup of tea. It opens the door to high-impact roles and can propel you all the way to the CFO's chair. As Warren Buffett said, 'The more you learn, the more you earn.' The CPA (US) journey brings that vision within reach,' said Vijay Narwani , CPA (US), and CPA (US) Educator, MYCPE ONE Academy.
Unlike traditional CPA (US) coaching programs that cost ₹1 – 1.5 lakhs, MYCPE ONE Academy's course ensures quality, structure, and support, at just ₹9,999 (~$120) .
To explore or enrol in the course, visit here
About MYCPE ONE Academy
MYCPE ONE Academy is an initiative by MYCPE ONE, with a mission to provide affordable and accessible global professional courses in areas such as Tax, Management, Accounting, Finance, and HR. For more details, visit https://academy.my-cpe.com/
Contact Information Vaibhav Jain Vice President MYCPE ONE Academy Phone: +91 6357 067952
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
2 Top Stocks to Buy Right Now
Even in volatile times such as now, good stocks can be had if one looks carefully and thoughtfully. Berkshire Hathaway remains an attractive investment despite its upcoming leadership change. Vertex Pharmaceuticals has room to grow in its core market and continues to innovate in new areas. 10 stocks we like better than Berkshire Hathaway › Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the uncertain near-term economic outlook. Even with these issues, though, stocks are likely to produce superior returns to most other assets over the next decade, as they have consistently done in the past. Moreover, when things are erratic, it can be a wise strategy to invest in companies that are positioned to perform well over the long term. Two great examples are Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX). Warren Buffett's recent announcement that he would step down from his longtime role as the CEO of Berkshire Hathaway by the end of this year will almost certainly come down as one of the most talked-about pieces of news on Wall Street this year. In the wake of that leadership change, some investors may decide to steer clear of the stock. After all, it was Buffett who led the conglomerate to market-crushing returns over the decades, not Greg Abel, his chosen successor. Further, Buffett is leaving at an unsteady time economically. Corporations are facing a rapidly shifting global trade environment. Macroeconomic troubles appear likely to take a toll on many companies, even those as strong as Berkshire Hathaway. Can Abel successfully take the reins of the conglomerate, especially at a time like this? In my view, the answer is yes. Buffett might be irreplaceable, but he leaves behind an incredibly robust and diversified business. Between Berkshire Hathaway's several dozen subsidiaries across an array of sectors and industries, its impressive stock portfolio, and its massive cash stockpile, it's positioned to handle severe economic shocks better than most companies. Not all of the company's businesses will be affected equally by macro turbulence. Some might thrive as others suffer -- it will average out, at least somewhat. Berkshire Hathaway might not come out of a recession (if one is on the way) completely unscathed, but it will come out on solid footing. And regarding the pending change in management, Buffett did not pick Abel out of a hat. As a top executive of the conglomerate, Abel has soaked up Buffett's investment philosophy, and he has been capably overseeing a large portion of the company for years. Nor will Abel be doing the job alone, any more than Buffett did it by himself. Many of Berkshire Hathaway's executives have been with the company for a long time and have contributed significantly to it achieving its current status as one of the few corporations with a trillion-dollar-plus market cap. The stock should continue to deliver superior returns in the long run under new management. That's why it's still worth investing in today. Vertex Pharmaceuticals' shares recently plunged after it announced its fiscal second-quarter results. Those were unimpressive, partly due to a non-cash impairment charge it took relating to an investigational medicine it is no longer pursuing, and partly due to the illegal sales of knock-off versions of its patented drugs in Russia, which took a slice out of its total revenues. However, these are relatively minor issues, at least when viewed in the broader context. Vertex remains the undisputed leader in cystic fibrosis therapies. This rare lung disease only affects about 94,000 patients in Vertex's core markets of North America, Europe, and Australia. But since it sells the only medicines that target the underlying causes of the condition, Vertex has substantial pricing power. That's why revenue and earnings have consistently increased at a good clip over the past decade, and there's reason to expect more growth to come. Cystic fibrosis patients now live longer than they once did, partly thanks to Vertex's breakthroughs. Unfortunately, they still need constant care. Therefore, its products continue to be in demand among these populations. Furthermore, Vertex is seeking to expand into new territories and develop more effective medicines, particularly for patients who would not benefit from its current treatments. Vertex's core franchise can still experience significant growth. Even if another company succeeds in developing competing cystic fibrosis therapies, the biotech's first-mover advantage and its relationship with patients, physicians, and third-party payers give it a leg up. Vertex has also expanded its portfolio with the approval of products such as Journavx for acute pain and Casgevy for beta-thalassemia and sickle cell disease. Its pipeline should yield more clinical and regulatory wins within the next two years. Vertex is an innovative biotech company with an incredibly strong underlying business. Beyond the company's dominance in cystic fibrosis, that's the core reason to buy the stock. It should deliver excellent results over the long term. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Berkshire Hathaway and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Berkshire Hathaway and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 2 Top Stocks to Buy Right Now was originally published by The Motley Fool
Yahoo
3 hours ago
- Yahoo
Warren Buffett Just Sold 1 Stock Up 196% Over the Past 3 Years and Piled Into Another Stock Down 25%. What Is He Thinking?
Berkshire Hathaway continues to build up an enormous cash position. Nu has massive opportunities, but there's risk in Latin America right now. By contrast, Constellation Brands offers stability in a volatile market. 10 stocks we like better than Constellation Brands › Warren Buffett and his team at Berkshire Hathaway continued their streak of selling more stocks than they bought in the 2025 first quarter, building up the company's cash pile to more than $347 billion. They sold eight stocks, including closing two positions. One of those was the struggling Citibank and the other was Nu Holdings (NYSE: NU), a soaring growth stock that's up 196% over the past three years. However, they still found seven stocks worthy of buying in the quarter, although they didn't start any new positions. Of particular interest was ramping up their position in Constellation Brands (NYSE: STZ), which is down 25% over the past three years. This could look like a value trap to the amateur investor, but Buffett clearly sees it as a buying opportunity. Let's see why Buffett might be thinking that it's time to sell Nu, a high-growth stock, and buy Constellation Brands, which is down in the dumps. Buffett is the classic contrarian investor, meaning he goes against what the rest of the market is doing. But he employs the classic investing method of buying low and selling high. He has explained many times over the years that it doesn't make much sense to buy stocks at highs or sell them at lows. He looks to buy when everyone else is selling, and prices are down, and he aims to sell when the market is enthusiastic, and prices are high. His most famous quote about this encapsulates this idea: "We simply attempt to be fearful when others are greedy and to be greedy only when others are fearful." Berkshire Hathaway invested in Nu, a digital bank, in a funding round just before its initial public offering in 2021, and it's done very well with this investment. However, it's not the holding company's typical stock pick. Buffett doesn't usually invest in young growth stocks, and he's not a big fan of technology. Nu still has massive growth opportunities. It's proven extremely popular in its headquarters of Brazil, where it already has 59% of the population as members and continues to grow at a high rate, and it's just getting started in Mexico and Colombia. It's highly profitable and consistently reports strong growth. What might be motivating Buffett to sell right now is the risk. Brazil has a high inflation rate, and Nu is feeling that right now it has increased provisions for losses and higher interest expenses. That, along with building out its business in Mexico and Colombia, is putting pressure on its margins. Being a proponent of the buy low, sell high philosophy, which underpins most successful investing, Buffett and his team might see this as an opportune time to move on to stable stocks that are more in line with their value approach to investing. Considering the deeper investment in Constellation Brands, as well as the other stocks Berkshire Hathaway extended its position in, there might be other factors at play, too. Buffett doesn't usually explain why he buys or sells stocks, and on rare occasions, he'll praise what he likes about a particular stock. But he freely gives advice about general investing, and that can give some clues about his own trades. He often talks about well-established businesses and strong brand names, and the investment in Constellation Brands, as well as the pullback from Nu, make sense if you understand what Buffett prizes. Constellation Brands makes alcoholic drinks under well-known labels like Corona beer and Casa Noble tequila. These are products that are always in demand, and the established brand names create a competitive advantage. Constellation Brands has reported lackluster growth over the past few years, but Buffett has his eye on the long term. He might also be considering the current uncertain economy and volatile market. It's more important in these times to hold onto secure stocks that can weather stormy seas. It also pays a growing dividend that yields 2.2% at the current price. Buffett loves dividends because they imply financial strength, stability, and a commitment to shareholders. On top of that, Constellation Brands stock looks cheap at today's price. It trades at a forward, 1-year P/E ratio of 13 and a price-to-cash flow ratio of 17, which is an attractive valuation. Constellation Brands stock likely won't appeal to the growth investor, but there would be long-term upside at the current price, and it offers the stability that features in most of Buffett's stocks. Before you buy stock in Constellation Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Constellation Brands wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Citigroup is an advertising partner of Motley Fool Money. Jennifer Saibil has positions in Nu Holdings. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends Constellation Brands and Nu Holdings. The Motley Fool has a disclosure policy. Warren Buffett Just Sold 1 Stock Up 196% Over the Past 3 Years and Piled Into Another Stock Down 25%. What Is He Thinking? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
